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Milan, Italy; and London, United KingdomObjectives This study sought to investigate the role of drug-eluting balloons (DEB) alone or in
combination with drug-eluting stents (DES) in the treatment of diffuse de novo coronary artery disease
(CAD) (>25 mm).
Background The use of DEB in diffuse CAD, either alone or in combination with DES, offers an
alternative to stenting alone. Data regarding DEB in this context are limited.
Methods We retrospectively evaluated all patients treated with DEB for diffuse CAD between June
2009 and October 2012. Endpoints analyzed were major adverse cardiac events, deﬁned as all-cause
death, myocardial infarction, and target vessel revascularization (TVR), as well as TVR and target lesion
revascularization separately. Results were compared with those obtained from a cohort of patients
with similar characteristics treated with DES alone.
Results A total of 69 patients (93 lesions) were treated with DEB  DES, and 93 patients with DES
alone (93 lesions). A high proportion of patients were diabetic (46.4% vs. 44.1%, p ¼ 0.77). Of the DEB-
treated lesions, 56.0% were treated with DEB alone, 7.4% with DEB and DES as bail out, and 36.6% with
DES and DEB as part of a hybrid approach for very long disease. Outcome rates with DEB  DES were
comparable to those with DES alone at 2-year follow-up (major adverse cardiac events ¼ 20.8% vs.
22.7%, p ¼ 0.74; TVR ¼ 14.8% vs. 11.5%, p ¼ 0.44; target lesion revascularization ¼ 9.6% vs. 9.3%, p ¼
0.84).
Conclusions DEB may have a role in the treatment of diffuse de novo CAD, either alone in smaller
vessels or in combination with DES in very long disease. (J Am Coll Cardiol Intv 2013;6:1153–9)
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1154The use of paclitaxel drug-eluting balloons (DEB) is an
emerging approach to the treatment of de novo coronary
disease and in-stent restenosis (1–4). Apart from the me-
chanical treatment of underlying disease after balloon in-
ﬂation, it allows the local release of an antirestenotic drug
without the use of a polymer or metal scaffold. This limits
cellular proliferation and restenosis associated with conven-
tional balloon angioplasty while at the same time overcomes
some of the limitations associated with drug-eluting stent
(DES) implantation such as the need for prolonged dual
antiplatelet therapy (DAPT) (5), the risk of late and very late
stent thrombosis (ST) (6), and the absence of a permanent
metal prosthesis within the vessel wall (7). In addition, the
implantation of long metal devices in coronary vessels may
impair restoration of vasomotion in the stented segment,
promote neoatherosclerosis, and limit access for coronaryAbbreviations
and Acronyms
CABG = coronary artery
bypass graft
DAPT = dual antiplatelet
therapy
DEB = drug-eluting balloon
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ST = stent thrombosis
TVR = target vessel
revascularization
TLR = target lesionartery bypass graft (CABG) (8).
Stent length is known to
independently predict in-stent
restenosis and thrombosis (9,10).
We previously demonstrated that
treatment with 60-mm over-
lapping DES, although associ-
ated with acceptable mortality
and ST rates, can lead to high
target lesion revascularization
(TLR) rates, approximating 24%
(11). Thus, the possibility of
using DEB alone or as part of
a hybrid procedure combining
DEB and DES to limit stent
length in vessels with diffuse
disease may be an alternative and
useful approach.
Here we report the data and
clinical outcomes from 2 high-
volume centers in Milan, Italy, ofpatients who underwent treatment with DEB alone or in
combination with DES for diffuse coronary artery disease
(CAD) and compare them with those of a cohort of patients
with similar characteristics treated over the same period with
DES alone.
Methods
We examined all DEB procedures performed at San Raf-
faele Scientiﬁc Institute and EMG-GVM Cento Cuore
Columbus in Milan from June 2009 until October 2012.
Each procedure was entered into a percutaneous coronary
intervention (PCI) database at the time of the procedure
and subsequently, all clinical parameters were veriﬁed by
inspecting the case records. Exclusion criteria included
DEB PCI for in-stent restenosis and de novo lesions
<25 mm. Using these criteria, 69 patients with 93 lesions
revascularizationwere identiﬁed. A separate cohort of 93 patients treated
over the same period with second-generation DES alone
was selected as a comparison group after matching for
clinically important characteristics such as diabetes, age,
ejection fraction, prevalence of multivessel disease, device
diameter, and treated lesion length. All patients provided
informed consent for both the procedure and subsequent
data collection and analysis. Patients received standard
DAPT before the procedure and continued this for 1
month after a DEB-only approach and for 12 months in
cases of DES implantation. Interventional approach,
intravascular ultrasound use, and administration of glyco-
protein IIb/IIIa receptor inhibitors during the procedure
were left to the discretion of the operator. In the DEB
group, bail-out stenting in cases of dissection or residual
stenosis was also left to the discretion of the operator. Stent
implantation in the DEB group was undertaken either as
part of a hybrid approach incorporating DEB and DES to
treat very long disease or to treat a dissection with signs of
lumen compromise or reduced ﬂow or when the residual
stenosis was evaluated to be greater than 50%.
Clinical follow-up and deﬁnitions. Clinical follow-up was
achieved for all recruited subjects by clinic visit or telephone
interview. Angiographic follow-up was not encouraged unless
clinically indicated or as part of a separate revascularization
procedure. Clinical outcomes reported represent patient-
speciﬁc data unless otherwise stated. The measured endpoints
were major adverse cardiac events (MACE) deﬁned as
a composite of all-cause death, myocardial infarction (MI)
(including periprocedural) and target vessel revascularization
(TVR). Death was considered cardiac in origin unless obvious
noncardiac causes were identiﬁed. We deﬁned post-proce-
dural non–Q-wave MI as a creatine kinase-myocardial
band increase of >3 times the upper limit of normal (12).
Creatine kinase was routinely measured after PCI in all
patients at both centers. Nonprocedural or spon-
taneous MI was deﬁned as an increase in troponin above
the upper range limit in combination with at least 1 of the
following: symptoms of ischemia; electrocardiographic
changes indicative of new ischemia; or the development of
pathological Q waves on electrocardiography. TVR was
deﬁned as repeat PCI or CABG of the target vessel. TLR
was deﬁned as repeat PCI or CABG for the lesion in the
previously treated segment or within the 5 mm proximal or
distal to the stent edge or site of DEB inﬂation. The
occurrence of ST was deﬁned on the basis of the Academic
Research Consortium deﬁnitions (13). Chronic total
occlusion was deﬁned as complete occlusion with Throm-
bolysis In Myocardial Infarction ﬂow grade of 0 lasting at
least 3 months. The European System for Cardiac Oper-
ative Risk Evaluation (EuroSCORE) (14) and the Synergy
Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery (SYNTAX) scores were calculated
(15). Diffuse disease was deﬁned as de novo CAD >25
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1155mm. Procedural success was deﬁned as completion of the
procedure with no in-lab complications, ﬁnal Thrombolysis
In Myocardial Infarction ﬂow of 3 with residual stenosis
<50%.
Quantitative coronary angiographicmeasurements. Matched
orthogonal views were used for quantitative analysis before
and after treatment. Angiography was performed after
intracoronary injection of nitroglycerin (100 to 200 mg).
Angiograms were analyzed by means of the Clinical
Measurements Solutions system (QCA-CMS version 5.1,
Medis Medical Imaging Systems, Leiden, the
Netherlands). Quantitative coronary analysis measurements
were performed at baseline and after device inﬂation.
Minimal lumen diameter, diameter stenosis, acute gain,
and reference vessel diameter of the treated segment were
measured.
Statistical analysis. Values are presented as mean  SD or
median (interquartile range) for continuous variables or as
count and percentage for categorical variables. Continuous
variables were compared by the independent sample Stu-
dent t or Mann-Whitney U tests. Categorical variables were
compared by the chi-square statistic or Fisher exact test. A
p value <0.05 was considered to be statistically signiﬁ-
cant, and all reported p values were 2 sided. Time-to-event
curves were generated using the Kaplan-Meier method.
Analyses were carried out using SPSS for Windows, version
19.0 (SPSS Inc., Chicago, Illinois).Table 1. Baseline Clinical Characteristics
DEB  D
(n
Age, yrs 66.5
Male 63 (
Ejection fraction, % 54.3
Previous myocardial infarction 37 (
Previous percutaneous intervention 40 (
Previous coronary artery bypass graft 13 (
Risk factors
Family history of ischemic heart disease 28 (
Hypertension 50 (
Hypercholesterolemia 47 (
Current smoker 9 (
Ex-smoker 39 (
Diabetes 32 (
Diet controlled 1 (
Oral hypoglycemics or insulin dependent 31 (
Acute coronary syndrome 11 (
Multivessel disease 49 (
EuroSCORE 3.23
SYNTAX score 23.7
Values are mean  SD or n (%).
DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent; EuroSCO
SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With TaxResults
Baseline patient characteristics. During the study period,
262 patients were treated with DEB, 69 of whom for diffuse
de novo CAD >25 mm. In these 69 patients, 93 lesions
were treated. Baseline patient demographic characteristics
for the patients treated with DEB  DES or DES alone are
demonstrated in Table 1. Mean age was similar in both
groups (66.5  10.4 years vs. 66.1  8.4 years, p ¼ 0.73) as
was ejection fraction (54.3  9.4% vs. 56.3  9.4%, p ¼
0.88). A high proportion of patients were diabetic in both
groups (46.4% vs. 44.1%, p ¼ 0.77). Multivessel disease was
present in the majority of the patients (71.0% vs. 73.1%, p ¼
0.77).
Angiographic and procedural details. Average treated lesion
length was similar between the DEB  DES and DES-
alone groups (47.3  18.1 mm vs. 47.6  18.6 mm, p ¼
0.88). Other angiographic and procedural characteristics
are summarized in Tables 2 and 3. With regard to the
DEB type used, the IN.PACT Falcon (Medtronic Inc.,
Santa Rosa, California) was used in the majority of cases
(n ¼ 81, 87.1%) with the Pantera Lux (Biotronik SE,
Berlin, Germany) being used in the remaining lesions. As
expected, the mean DES diameter was greater in the DEB
 DES group compared with the DES-alone group (2.95 
0.42 mm vs. 2.79  0.25 mm, p < 0.01) as DES use in
the former was in general at the more proximal part ofES Strategy
¼ 69)
DES-Alone Strategy
(n ¼ 93) p Value
 10.4 66.1  8.4 0.73
91.3) 77 (82.8) 0.12
 9.4 56.3  9.4 0.77
53.6) 45 (48.4) 0.51
58.0) 42 (45.2) 0.11
18.8) 19 (20.4) 0.80
40.6) 34 (36.6) 0.60
72.5) 64 (68.9) 0.62
68.1) 65 (69.9) 0.81
13.01) 14 (15.1) 0.72
56.5) 38 (40.9) 0.05
46.4) 41 (44.1) 0.77
1.4) 3 (3.2) 0.47
44.9) 38 (40.9) 0.60
15.9) 12 (12.9) 0.58
71.0) 68 (73.1) 0.77
 2.28 3.11  1.94 0.69
 10.3 21.5  8.7 0.14
RE ¼ European System for Cardiac Operative Risk Evaluation;
us and Cardiac Surgery.
Table 4. Quantitative Coronary Angiography Measurements in
the Treated Segment at Baseline and After the Procedure
Characteristic
DEB  DES
Strategy
(n ¼ 93)
DES-Alone
Strategy
(n ¼ 93) p Value
Baseline
Reference vessel diameter, mm 2.44  0.37 2.58  0.29 <0.01
Minimal lumen diameter, mm 0.66  0.30 0.67  0.26 0.68
Diameter stenosis, % 72.9  11.3 73.9  10.7 0.58
Length, mm 47.3  18.1 47.6  18.6 0.88
Final
Minimal lumen diameter, mm 1.78  0.41 2.19  0.37 <0.01
Diameter stenosis, % 26.5  7.93 15.6  4.98 <0.01
Acute gain, mm 1.12  0.45 1.52  0.44 <0.01
Values are mean  SD.
Abbreviations as in Table 1.
Table 2. Lesion and Procedural Characteristics
Characteristic
DEB  DES
Strategy
(n ¼ 93)
DES-Alone
Strategy
(n ¼ 93) p Value
Vessel treated 0.48
Left anterior descending artery 37 (39.8) 43 (46.2)
Circumﬂex artery 16 (17.2) 18 (19.4)
Right coronary artery 40 (43.0) 32 (34.4)
Location of lesion in treated vessel 0.10
Proximal 4 (4.3) 10 (10.8)
Mid/distal 89 (95.7) 83 (89.2)
Balloon pre-dilation 80 (86.0) 84 (90.3) 0.36
Procedural adjuncts
IVUS 37 (39.8) 30 (32.3) 0.28
Rotablation 3 (3.2) 4 (4.3) 0.70
Device characteristics
DEB diameter, mm 2.52  0.29 NA
DES diameter, mm 2.95  0.42 2.79  0.25 <0.01
Total stent length,* mm 29.0  9.1 50.2  18.2 <0.01
Values are n (%) or mean  SD. *DEB  DES (n ¼ 41), DES alone (n ¼ 93).
IVUS ¼ intravascular ultrasound; NA ¼ not applicable; other abbreviations as in Table 1.
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1156the lesion, with the exception of bail-out stenting. Of the
DEB-treated cases, bail-out stenting was required in 7.4% of
cases. A hybrid approach, using the combination of a DES
and a DEB, for treating very long disease (67.7  13.4 mm)
was used in 34 lesions (36.6%). In these cases, a DEB was
used more distally compared with a DES, with an overall
DEB/DES ratio of 1.24, suggesting that a DEB rather
than a DES treated a greater lesion length. Quantitative
coronary angiography measurements at baseline and at the
end of the procedure for the 2 groups are reported in
Table 4. The acute post-procedural result was better after
stenting alone compared with balloon angioplasty, with less
residual stenosis and a greater acute gain in the DES alone
group.
Clinical follow-up. Clinical outcomes over the entire follow-
up period (median, 26.1 months; interquartile range, 13.4 to
31.5 months) are summarized in Table 5. Aside from the
cases of periprocedural MI, there were no other in-hospital
events recorded in the DEB DES group. There was 1 caseTable 3. Strategies Used in the Treatment of Diffuse Disease Using DEB
Treatment
Strategy
Lesion
(n ¼ 93)
Lesion
Length, mm
% Lesion Length
Covered by DES
DEB/DES
Length Ratio in
Treated Segment
DEB alone 52 (56.0) 35.4  5.7 NA NA
Sequential (hybrid)
DEB and DES
34 (36.6) 67.7  13.4 44.6  15.3 1.24
DEB with DES
bail out
7 (7.4) 36.7  5.2 39.9  8.8 1.51
Values are n (%) or mean  SD.
Abbreviations as in Table 2.of acute ST in the DES-alone group that occurred in
a patient who received a 3.0  38-mm everolimus-eluting
stent (EES) for a mid left anterior descending artery lesion.
Estimated MACE and TVR rates at 2-year follow-up
(Figs. 1 and 2) were similar and not signiﬁcantly different
between the DEB  DES and DES-alone groups (20.8 
6.1% vs. 22.7  4.5%, p ¼ 0.74 and 14.8  5.7% vs. 11.5 
3.4%, p ¼ 0.44). Estimated TLR rates per patient and per
lesion were also comparable over the same follow-up period
(9.6  4.6% vs. 9.3  3.2%, p ¼ 0.836 and 8.0  3.9% vs.
9.3  3.2%, p ¼ 0.858). With regard to the TLR cases
observed in the DEB  DES group, 3 of these occurred in
patients who received both a DEB and DES as part of
a hybrid strategy (2 in the DES-treated segment and 1 in the
DEB-treated segment) to treat very long disease and 2 in
patients treated with DEB alone. There were no cases of
vessel thrombosis in the DEB-treated group.Discussion
The main ﬁnding of our study is that DEB use, either alone
in smaller diameter vessels or in combination with DES for
very long disease, is an acceptable approach for the treatment
of diffuse CAD, associated with MACE, TVR, and TLR
rates similar to those seen with a DES-alone approach at
long-term follow-up.
DEB are becoming increasingly used in the treatment of
CAD, especially in the setting of in-stent restenosis (16).
Recent studies have also evaluated the role of DEB in the
treatment of de novo CAD. The Pilot Long Lesion Study
examining optimal balloon angioplasty followed by DEB
and spot bare-metal stenting on an as-needed basis reported
reasonable TLR rates, although only 12 patients were
recruited (17). The STARDUST (Spot Bare-Metal Stent-
ing Provisional Implantation plus Drug-Eluting Balloon
Against Drug-Eluting Stenting) trial, currently recruiting,
Table 5. Cumulative Clinical Events
Clinical Outcomes
DEB  DES Strategy
(n ¼ 69)
DES-Alone Strategy
(n ¼ 93)
In-hospital events
MI 3 (4.3) 5 (5.4)
ST (deﬁnite/probable) 0 1 (1.1)
Death 0 0
Follow-up events
Death 4 (5.8) 6 (6.5)
Cardiac cause 2 (2.9) 2 (2.2)
Noncardiac cause 2 (2.9) 4 (4.3)
TVR 8 (11.6) 13 (14.0)
TLR 5 (7.2) 10 (10.8)
MI 0 1 (1.1)
ST (deﬁnite/probable) 0 0
MACE* 13 (18.8) 23 (24.7)
TLR (per lesion) 5/93 (5.4) 10/93 (10.8)
Values are n (%) or n/N (%). *MACE is deﬁned as all-cause death, TVR, and MI (including peri-
procedural).
MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; ST ¼ stent thrombosis;
TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations
as in Table 1.
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1157is examining this further. The prospective randomized
BELLO (Balloon Elution and Late Loss Optimization)
study examining the role of DEB in small coronary vessels
with visual reference diameter <2.8 mm and lesion length
<25 mm demonstrated similar MACE rates between
paclitaxel-eluting stents and DEB at 6-month follow-up
(16.3% vs. 10%, p ¼ 0.21) (4). Reference vessel diameter of
the DEB treated vessels in our study was as expected, similar
to that observed in the BELLO study (2.25 mm vs. 2.15
mm) and reﬂects the interventionist’s tendency toward DEB
use in small coronary vessels, especially in the context of
diffuse disease. A hybrid approach, using both DES and
DEB, was used in patients with very long lesions, whichFigure 1. Kaplan-Meier Time-to-Event Curve for MACE
Kaplan-Meier curves for MACE according to strategy used. DEB ¼ drug-eluting
balloon(s); DES ¼ drug-eluting stent(s); MACE ¼major adverse cardiac events.comprised approximately a third of the lesions treated. In
these cases, DES were used in the larger, more proximal
lesion site and DEB in the more distal, smaller part.
Advantages of such a hybrid approach include the reduction
of overall stent length, a predictor of in-stent restenosis and
ST while maintaining access for a future CABG if required.
A decrease in metal stent length may also preserve the
vessel’s response to vasomotion stimuli and reduce the risk of
neoatherosclerosis (7). The procedural efﬁcacy of a DEB
strategy in our study is evident by the acceptable residual
percentage of diameter stenosis and bail-out stent rate, both
of which are comparable with previous DEB studies (4,18).
The differences in procedural efﬁcacy with regard to acute
gain and percentage of diameter stenosis between a DES-
alone strategy and a strategy using a DEB should be ex-
pected in view of the absence of a permanent metal scaffold
where a DEB has been used. Similar results had been re-
ported in previous studies comparing balloon angioplasty
with bare-metal stent implantation (19).
With regard to the clinical outcomes observed with
a strategy using a DEB, these were not dissimilar to those
reported by the BELLO study (MACE ¼ 10%,
TVR ¼ 7.8% at 6 months) and the Valentines II registry
(MACE ¼ 8.7%, TVR ¼ 6.9% at 8 months), despite
differences in lesion length (lesions >25 mm were excluded
in both of these studies) (4,18). More importantly, the
clinical outcomes observed with a DEB  DES approach
were similar to those seen in patients with a similar risk
factor proﬁle and lesion length who were treated with
a DES alone. In agreement with this, the incidence of
MACE at 1 year (10.4%) in the DEB  DES group does
not appear to differ signiﬁcantly from that observed in
the prospective LONG-DES III (Percutaneous Treatment
of LONG Native Coronary Lesions With Drug-Eluting
Stent-III) trial in which patients with lesion length
>25 mm experienced MACE rates of 14.3% and 10.2%Figure 2. Kaplan-Meier Time-to-Event Curve for TVR
Kaplan-Meier curves for TVR according to strategy used. TVR ¼ target vessel
revascularization; other abbreviations as in Figure 1.
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1158at 1-year follow-up with EESs and sirolimus-eluting
stents, respectively (20). Although TVR rates in this study
were lower, at 4% with EES and 2.7% with sirolimus-
eluting stents, than those observed in our study over the
same time interval, it is important to note that in the
LONG-DES III trial, larger vessels were treated and
the prevalence of diabetes mellitus was lower. Moreover,
a pooled analysis from the SPIRIT (Clinical Evaluation
of the XIENCE V Everolimus Eluting Coronary Stent
System) and COMPARE (Second-Generation Ever-
olimus-Eluting and Paclitaxel-Eluting Stents in Real-Life
Practice) randomized trials demonstrated MACE and
TLR rates at 2 years in a subgroup of patients treated with
either EESs or paclitaxel-eluting stents for disease in
vessels with a lesion length >13.4 mm and a reference
lumen diameter <2.65 mm of 5.5% and 7.6%, respectively
(21). Although these are lower than the ones we have
observed, treated length was much shorter in this analysis
(mean length, 28.7 mm), and MACE deﬁnition was less
liberal compared with our study. Furthermore, as was the
case with the LONG DES III trial, the prevalence of
diabetes mellitus was also much lower.
Our study suggests that DEB use can be an alternative
approach to the use of DES for the treatment of diffuse
coronary disease, either alone in the smaller coronary
vessels or in combination with DES in very long lesions.
Use of DEB in such circumstances can reduce overall stent
length and stent use in small vessels, both of which are
predictors of ST and TLR, while treating the underlying
disease and maintaining access for a future CABG if re-
quired. It is also an attractive option when used alone for
patients who cannot tolerate prolonged DAPT. Further
studies are required to fully evaluate the role of DEB in
this setting.
Study limitations. First, this was a retrospective observa-
tional study with a small number of patients, with not all
patients completing the 2-year follow-up. Second, the lack
of systematic angiographic follow-up did not allow us to
assess the angiographic efﬁcacy of DEB in the DEB-treated
segments. Third, some patients in our cohort had already
experienced in-stent restenosis in a different coronary vessel,
and, thus, it may be that part of our cohort was “inherently”
predisposed to restenosis, which could have led to higher
TLR rates. Finally, angina burden, an important clinical
parameter, was not included in the follow-up data.Conclusions
Our data suggest that DEB may have a role in the treatment
of diffuse coronary disease, either alone in smaller vessels or
in combination with DES, in very long disease. Such an
approach is associated with acceptable long-term clinical
outcomes, similar to those seen with a DES-alone strategy.Further studies are required to evaluate the role of DEB in
this setting.
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